CIK 0001561921
- Non-accelerated filer
- Smaller reporting company
TELA Bio, Inc.
Sign in to watch- Ticker
- TELA
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 455320061
- Phone
- +1 484-320-2930
- Business address
- 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA, 19355
- Open-market buys, last 90 days
- $167,238
- in 2 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$167,238. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-04-03 | EW HEALTHCARE PARTNERS FUND 2, L.P. 10% owner | Purchase | +9,634 | $8.01 | $77K | 1,193,865 |
| 2020-04-02 | EW HEALTHCARE PARTNERS FUND 2, L.P. 10% owner | Purchase | +15,000 | $8.01 | $120K | 1,184,231 |
| 2020-04-01 | EW HEALTHCARE PARTNERS FUND 2, L.P. 10% owner | Purchase | +15,000 | $7.47 | $112K | 1,169,231 |
| 2020-01-27 | Murphy Peter C. Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2019-12-17 | RTW INVESTMENTS, LP 10% owner | Sale | −36,000 | $11.32 | $408K | 1,139,358 |
| 2019-12-13 | RTW INVESTMENTS, LP 10% owner | Purchase | +23,900 | $11.60 | $277K | 1,175,358 |
| 2019-11-13 | KOBLISH ANTONY Chief Executive Officer | Conversion | +7,277 | 139,860 | ||
| 2019-11-13 | KOBLISH ANTONY Chief Executive Officer | Conversion | +14,225 | 154,085 | ||
| 2019-11-13 | KOBLISH ANTONY Chief Executive Officer | Conversion · Series A Preferred Stock | −179,685 | 0 | ||
| 2019-11-13 | KOBLISH ANTONY Chief Executive Officer | Conversion · Series B Preferred Stock | −351,271 | 0 | ||
| 2019-11-13 | KOBLISH ANTONY Chief Executive Officer | Conversion · Warrant (right to buy) | −10,775 | 0 | ||
| 2019-11-13 | KOBLISH ANTONY Chief Executive Officer | Conversion · Warrant (right to buy) | −10,775 | 10,775 | ||
| 2019-11-13 | Ellis Ronald J. Jr. Director | Conversion | +580,357 | 774,056 | ||
| 2019-11-13 | Ellis Ronald J. Jr. Director | Conversion · Series B Preferred Stock | −14,329,052 | 0 | ||
| 2019-11-13 | Quaker BioVentures II LP 10% owner | Conversion | +345,489 | 1,234,153 | ||
| 2019-11-13 | Quaker BioVentures II LP 10% owner | Conversion | +516,947 | 1,751,100 | ||
| 2019-11-13 | Quaker BioVentures II LP 10% owner | Conversion · Series A Preferred Stock | −8,530,145 | 0 | ||
| 2019-11-13 | Quaker BioVentures II LP 10% owner | Conversion · Series B Preferred Stock | −12,763,434 | 0 | ||
| 2019-11-13 | Quaker BioVentures II LP 10% owner | Conversion · Warrant (right to buy) | −446,813 | 0 | ||
| 2019-11-13 | Quaker BioVentures II LP 10% owner | Conversion · Warrant (right to buy) | −446,813 | 446,813 |
Page 25 of 29 · 565 trades